[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.186.91. Please contact the publisher to request reinstatement.
Article
April 1989

Clonidine Treatment of Alzheimer's Disease

Author Affiliations

From the Medical Neurology Branch (Drs Mohr and Fedio) and the Experimental Therapeutics Branch (Drs Schlegel, Fabbrini, Mouradian, Mann, Claus, and Chase and Ms Williams), National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, Md.

Arch Neurol. 1989;46(4):376-378. doi:10.1001/archneur.1989.00520400030015
Abstract

• A loss of cortical noradrenergic innervation may contribute to the intellectual deterioration in Alzheimer's disease. To test the hypothesis that noradrenergic replacement may confer symptomatic benefit, a double-blind, placebo-controlled therapeutic trial with clonidine hydrochloride (Catapres), a centrally active noradrenergic receptor agonist, was undertaken in eight patients with the clinical diagnosis of Alzheimer's disease. No statistically significant changes in cognitive function were found over a range of doses, including those that produced clinically observable side effects. These preliminary results indicate a need for alternative noradrenergic replacement strategies in Alzheimer's disease.

×